Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Immunomodulatory Effects of Novel Nano Micelle Based Curcumin in Rheumatoid Arthritis Patients: A Double Blind Randomized Clinical Trial Publisher



Khamar F1 ; Atabaki M2 ; Samadi M3 ; Reisi M1 ; Sandoughi M4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Immunology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran
  2. 2. Clinical Immunology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran
  3. 3. Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Rheumatologis, Department of Internal Medicine, Ali Ebn Abitaleb Hospital, Zahedan University of Medical Sciences, Zahedan, Iran

Source: Rheumatology and Immunology Research Published:2024


Abstract

Background and Objectives: Rheumatoid arthritis (RA) is a well-known systemic autoimmune inflammatory disease. This investigation aimed to assess the effects of Sina-curcumin, a novel nano micelle-based curcumin, on immune system responses of RA patients. Methods: This pilot study is a randomized double blinded, controlled trial. Patients who fulfilled the European League against Rheumatism-American College of Rheumatology (EULAR-ACR) criteria for RA were assigned to receive curcumin or placebo for 12 weeks. The outcomes of this study were comparison of changes in mean value of Disease Activity Score of 28 joints erythrocyte sedimentation rate (DAS28-ESR), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), frequency of T helper 1 and T helper 2 cells population. Results: From 150 RA patients who were assessed for eligibility, data from 30 patients (15 patients in each group) were analyzed. There was no significant difference between the two groups regarding age (P = 0.6441) and body mass index (BMI, P = 0.6016). Our measurement showed a statistically significant reduction in ESR (P < 0.0001), CRP (P < 0.0001) and a non-significant decrease in DAS28-ESR (P = 0.5125) in the curcumin group. Also, the Th1/Th2 ratio favorably decreased in the curcumin group. This finding was due to a significant increase in Th2 cells (P < 0.0001) and a nonsignificant decrease in Th1 cells (P = 0.1532). Conclusion: Our trial findings revealed the immunomodulatory effects of curcumin. It could be used and recommended as adjunctive treatment for RA patients. © 2024 Faezeh Khamar, Mahdi Atabaki, Morteza Samadi, Marzieh Reisi, Mahnaz Sandoughi, published by De Gruyter on behalf of NCRC-DID.
Other Related Docs